Acta Medica Iranica 2018. 56(3):166-169.

Bone Structure-Related Biomarkers in Hemophilic Patients, Compared to Healthy Condition
Alireza Abdollahi, Gholamreza Toogeh, Sahba Gharechahi, Katayoun Ziari

Abstract


The increased risk for developing loss of bone density in patients with hemophilia has been recently regarded. The present study was conducted to compare the levels of vitamin D and other biochemical factors affecting bone turnover in patients with hemophilia and those without this problem. The study participants were stratified into the following subgroups 1) the hemophilic patients without evidence of viral infections, 2) those with the healthy condition without evidence of infection by the viral infections. All subjects were asked to take venous blood sample to assess the levels of serum biomarkers related to bone metabolism and turnover. Comparison of different biochemical markers related to bone metabolism and turnover showed significantly lower free testosterone, total testosterone, thyroid stimulating hormone (TSH), vitamin D, calcium, osteocalcin, calcitonin, and parathormone levels as well as higher serum alkaline phosphatase, Serum C-telopeptide (CTX), and N-terminal telopeptide (NTx) levels in those hemophilic patients as compared to control group. Hemophilia can adversely affect bone structure leading to bone loss in hemophilic patients. An appropriate screening protocol pertaining to osteoporosis must be implemented in the facilities for hemophiliac patients, so that preventive and healthcare measures like more physical activity and consumption of vitamin D and calcium supplements could be provided.


Keywords


Bone structure-related biomarkers; Hemophilic patients

Full Text:

PDF

References


(1) Kovacs CS. Hemophilia, low bone mass, and osteopenia/osteoporosis. Transfus Apher Sci. 2008;38(1):33–40. doi: 10.1016/j.transci.2007.12.003.

(2) Gerstner G, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009;15(2):559–565. doi: 10.1111/j.1365-2516.2008.01963.x.

(3) Christoforidis A, Economou M, Papadopoulou E, Kazantzidou E, Gompakis N, Athanassiou-Metaxa M. Bone status of children with hemophilia A assessed with quantitative ultrasound sonography (QUS) and dual energy X-ray absorptiometry (DXA) J Pediatr Hematol Oncol. 2010;32(7):e259–e263. doi: 10.1097/MPH.0b013e3181e8cd40.

(4) Roushan N, Meysamie A, Managhchi M, Esmaili J, Dormohammadi T. Bone mineral density in hemophilia patients. Indian J Hematol Blood Transfus. 2014 Dec;30(4):351-5.

(5) Gerstner G1, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009 Mar;15(2):559-65. doi: 10.1111/j.1365-2516.2008.01963.x. Epub 2009 Feb 1.

(6) Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1861–70.

(7) Anagnostis P1, Karras S, Paschou SA, Goulis DG. Haemophilia A and B as a cause for secondary osteoporosis and increased fracture risk. Blood Coagul Fibrinolysis. 2015 Sep;26(6):599-603. doi: 10.1097/MBC.0000000000000330.

(8) Kempton CL1, Antoniucci DM2, Rodriguez-Merchan EC3,4. Bone health in persons with haemophilia. Haemophilia. 2015 Sep;21(5):568-77. doi: 10.1111/hae.12736. Epub 2015 Jul 14.

(9) Eldash HH1, Atwa ZT, Saad MA. Vitamin D deficiency and osteoporosis in hemophilic children: an intermingled comorbidity. Blood Coagul Fibrinolysis. 2016 Jan 28. (Epub ahead of print)

(10) Kempton CL1, Antoniucci DM2, Rodriguez-Merchan EC3,4. Bone health in persons with haemophilia. Haemophilia. 2015 Sep;21(5):568-77. doi: 10.1111/hae.12736. Epub 2015 Jul 14.

(11) Albayrak C1, Albayrak D. Vitamin D levels in children with severe hemophilia A: an underappreciated deficiency. Blood Coagul Fibrinolysis. 2015 Apr;26(3):285-9. doi: 10.1097/MBC.0000000000000237.

(12) Alioglu B1, Selver B, Ozsoy H, Koca G, Ozdemir M, Dallar Y. Evaluation of bone mineral density in Turkish children with severe haemophilia A: Ankara hospital experience. Haemophilia. 2012 Jan;18(1):69-74. doi: 10.1111/j.1365-2516.2011.02587.x. Epub 2011 Jun 9.

(13) Ranta S1, Viljakainen H, Mäkipernaa A, Mäkitie O. Hypercalciuria in children with haemophilia suggests primary skeletal pathology. Br J Haematol. 2011 May;153(3):364-71. doi: 10.1111/j.1365-2141.2011.08639.x. Epub 2011 Mar 10.

(14) Avgeri M1, Papadopoulou A, Platokouki H, Douros K, Rammos S, Nicolaidou P, Aronis S. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008 Aug;30(8):592-7. doi: 10.1097/MPH.0b013e31817541a8.

(15) Anagnostis P1, Karras S, Paschou SA, Goulis DG. Haemophilia A and B as a cause for secondary osteoporosis and increased fracture risk. Blood Coagul Fibrinolysis. 2015 Sep;26(6):599-603. doi: 10.1097/MBC.0000000000000330.

(16) Wells AJ1, McLaughlin P, Simmonds JV, Prouse PJ, Prelevic G, Gill S, Chowdary P. A case-control study assessing bone mineral density in severe haemophilia A in the UK. Haemophilia. 2015 Jan;21(1):109-15. doi: 10.1111/hae.12565. Epub 2014 Nov 7.

(17) Anagnostis P1, Karras SN, Goulis DG. Bone disease in patients with haemophilia A and B--where are we now? Haemophilia. 2015 Jan;21(1):1-3. doi: 10.1111/hae.12551. Epub 2014 Sep 23.

(18) Anagnostis P1, Vakalopoulou S, Slavakis A, Charizopoulou M, Kazantzidou E, Chrysopoulou T, Vyzantiadis TA, Moka E, Agapidou A, Garipidou V. Reduced bone mineral density in patients with haemophilia A and B in Northern Greece. Thromb Haemost. 2012 Mar;107(3):545-51. doi: 10.1160/TH11-08-05563. Epub 2012 Feb 8.

(19) Gerstner G1, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009 Mar;15(2):559-65. doi: 10.1111/j.1365-2516.2008.01963.x. Epub 2009 Feb 1.

(20) Toogeh G, Abolghasemi H, Eshghi P, Managhchi M, Shaverdi-Niasari M, Karimi K,et al. Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study). Iran J Pathol. 2016 Summer;11(3):204-209.

(21) Etminani-Esfahani M, Khalili H, Jafari S, Abdollahi A, Dashti-Khavidaki S. Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes. 2012 Apr 26;5:204.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.